Key Insights

Highlights

Success Rate

82% trial completion

Published Results

11 trials with published results (15%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

8.5%

6 terminated out of 71 trials

Success Rate

81.8%

-4.7% vs benchmark

Late-Stage Pipeline

8%

6 trials in Phase 3/4

Results Transparency

41%

11 of 27 completed with results

Key Signals

11 with results82% success

Data Visualizations

Phase Distribution

57Total
Not Applicable (16)
Early P 1 (1)
P 1 (15)
P 2 (19)
P 3 (4)
P 4 (2)

Trial Status

Completed27
Unknown25
Recruiting7
Terminated6
Not Yet Recruiting3
Withdrawn2

Trial Success Rate

81.8%

Benchmark: 86.5%

Based on 27 completed trials

Clinical Trials (71)

Showing 20 of 20 trials
NCT04322136Not ApplicableCompletedPrimary

AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion

NCT02122185Phase 2Completed

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT07443020Phase 1Not Yet RecruitingPrimary

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

NCT07192900Phase 1RecruitingPrimary

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

NCT04914598Phase 3Active Not RecruitingPrimary

A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions

NCT02649894Not ApplicableCompletedPrimary

Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter

NCT05620329Recruiting

UNC Pleural Fluid Registry

NCT03235999CompletedPrimary

The Experiences of Patients Living With Malignant Pleural Effusions

NCT07147270Not ApplicableRecruiting

Impact of Patient Position on Chemical Pleurodesis by Chest Ultrasound

NCT06657638CompletedPrimary

Cytological Examination of Malignant Pleural Effusion in Breast Cancer

NCT06016179Phase 1RecruitingPrimary

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

NCT06964321Not ApplicableNot Yet RecruitingPrimary

Effectiveness of Intercostal Tube Drainage Vs Pigtail Catheter Drainage Vs Ultrasound-Guided Aspiration in Management of Massive Malignant Pleural Effusion

NCT06726564Phase 1Recruiting

A Study of MT027 in Patients with Pleural Malignant Tumors

NCT04985357Withdrawn

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

NCT06691009Not ApplicableNot Yet RecruitingPrimary

Pleural Bleomycin vs Mechanical Abrasion in Malignant Pleural Effusion

NCT06682936Not ApplicableRecruitingPrimary

Feasibility of Ambulatory Talc. Pleurodesis

NCT06421610Phase 1RecruitingPrimary

OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.

NCT03414905CompletedPrimary

Management of Malignant Pleural Effusions Using an Indwelling Tunneled Pleural Catheter and Non-Vacuum Collection System

NCT05278975Phase 1UnknownPrimary

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

NCT04792970Phase 4TerminatedPrimary

Randomized Controlled Trial of Talc Instillation In Addition To Daily Drainage Through a Tunneled Pleural Catheter to Improve Rates of Outpatient Pleurodesis in Patients With Malignant Pleural Effusion

Scroll to load more

Research Network

Activity Timeline